SDG 3. GOOD HEALTH & WELL-BEING Verge Genomics

Verge Genomics Names Robert Scannevin, Ph.D., Chief Scientific Officer

May 6, 2021, by Business Wire Technology News

SAN FRANCISCO–(BUSINESS WIRE)–Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today ...

Read more on Business Wire Technology News


SDG 3. GOOD HEALTH & WELL-BEING Verge Genomics

Verge Genomics Names Robert Scannevin, Ph.D., Chief Scientific Officer

May 6, 2021, by Business Wire Technology News

SAN FRANCISCO–(BUSINESS WIRE)–Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today ...

Read more on Business Wire Technology News


SDG 3. GOOD HEALTH & WELL-BEING Verge Genomics

How Verge Genomics Uses AI To Tackle Parkinson’s, Alzheimer’s And ALS

April 29, 2021, by Aayushi Pratap, Forbes Staff

Using a combination of machine learning and proprietary data, CEO Alice Zhang is looking to develop more powerful treatments for neurodegenerative disease.

Read more on Forbes - AI


SDG 3. GOOD HEALTH & WELL-BEING Verge Genomics

7 start-ups transforming the world of healthcare

February 24, 2021, by Kelly Earley

It has now been more than six months since the director general of the World Health Organization (WHO) declared the outbreak of Covid-19 to be ...

Read more on Silicon Republic


SDG 3. GOOD HEALTH & WELL-BEING Verge Genomics

7 start-ups transforming the world of healthcare

February 12, 2021, by Kelly Earley

It has now been more than six months since the director general of the World Health Organization (WHO) declared the outbreak of Covid-19 to be ...

Read more on Silicon Republic


SDG 3. GOOD HEALTH & WELL-BEING Verge Genomics

Verge Genomics Announces Research Collaboration with the Sheffield Institute for Translational Neuroscience

February 10, 2021, by PRWeb - Daily News Feed

A collaboration focused on the validation of new drug targets for the treatment of Parkinson’s Disease (PRWeb February 02, 2021) Read the full story at ...

Read more on PRWeb - Daily News Feed